CL 188,624, CL 190,294, and CL 191,121 are novel aminomethyl tetrahydrofuranyl (THF)-1␤-methylcarbapenems. The in vitro antibacterial activities of these THF carbapenems were evaluated and compared with those of biapenem, imipenem, and meropenem against 554 recent clinical isolates obtained from geographically distinct medical centers across North America. The antibacterial activities of the THF carbapenems were equivalent to that of biapenem, and the THF carbapenems were slightly more active than imipenem and less active than meropenem against most of the members of the family Enterobacteriaceae but lacked significant activity against Pseudomonas isolates. In general, CL 191,121 was two-to fourfold more active than CL 188,624 and CL 190,294 against the staphylococcal and enterococcal isolates tested. CL 191,121 was twofold less active than imipenem against methicillin-susceptible staphylococci and was as activity as imipenem against Enterococcus faecalis isolates. Biapenem and meropenem were two-and fourfold less active than CL 191,121, respectively, against the methicillin-susceptible staphylococci and E. faecalis. All the carbapenems displayed equivalent good activities against the streptococci. Biapenem was slightly more active than the other carbapenems against Bacteroides fragilis isolates. Time-kill curve studies demonstrated that the THF carbapenems were bactericidal in 6 h against Escherichia coli and Staphylococcus aureus isolates. The postantibiotic effect exerted by CL 191,121 was comparable to or slightly longer than that of imipenem against isolates of S. aureus, E. coli, and Klebsiella pneumoniae.
MATERIALS AND METHODS
Organisms. The 554 organisms (356 gram-negative and 174 gram-positive aerobes and 24 anaerobes) used for this study represent recent clinical isolates (1987 to 1993) from various medical centers and hospital outbreaks referred to the Antimicrobial Chemotherapy laboratory. The identification of the organisms in the cultures was performed by conventional methods: gram-negative rods were identified with the API 20E (Analytab Products, Plainville, N.Y.) and NF (Remel, Lenexa, Kans.) systems, the staphylococci were identified with StaphTrac (Analytab Products), and anaerobes were identified by methods described in the Wadsworth Anaerobic Bacteriology Manual (24) . The susceptibility of the staphylococci to oxacillin was determined by the presence or absence of growth on an agar plate supplemented with 4% NaCl and containing 6 g of oxacillin per ml and incubated at 35°C for 24 h (23). All isolates were stored frozen in skim milk at Ϫ70°C.
Antibiotics. Standard powders of CL 188,624 (3,5-trans diastereomers), CL 190,294 (3,5-cis diastereomers), and CL 191,121 (3,2, optically pure) were synthesized as described elsewhere (12) . Biapenem was obtained from WyethAyerst Research, Pearl River, N.Y.; imipenem was obtained from Merck Sharp & Dohme, West Point, Pa.; meropenem was obtained from Zeneca, Chesire, United Kingdom; ceftazidime was obtained from Glaxo-Wellcome, Research Triangle Park, N.C.; oxacillin was obtained from Sigma Chemical Co., St. Louis, Mo.; and penicillin was obtained from the United States Pharmacopeia.
Susceptibility tests. The in vitro determination of the MICs was performed by the microtiter method as recommended by the National Committee for Clinical Laboratory Standards (16) . Mueller-Hinton broth was used for assays with members of the family Enterobacteriaceae, staphylococci, and enterococci. The streptococci were tested in Mueller-Hinton broth supplemented with 5% sheep blood. Haemophilus test medium was used for assays with Haemophilus influenzae isolates. Microtiter plates in which each well contained 50 l of twofold serial dilutions of the antimicrobial agents in the appropriate broth were inoculated with 50 l of inoculum to yield a final density of 1 ϫ 10 5 to 5 ϫ 10 5 CFU/ml. Anaerobic bacteria were tested on Wilkins Chalgren agar supplemented with 5% lysed sheepblood and 0.001% vitamin K. The MICs were determined after 18 to 22 h of incubation at 35°C in ambient air for the aerobic bacteria and after 48 h in an anaerobic chamber (Coy Laboratories, Ann Arbor, Mich.) for the anaerobes. The MIC was defined as the lowest concentration of the antimicrobial agent that completely inhibits growth of the organism as detected by the unaided eye.
Time-kill curve studies. Bactericidal activity was determined by the time-kill curve method recommended by the National Committee for Clinical Laboratory Standards (17) . Flasks containing 50 ml of the appropriate antimicrobial agent were inoculated with 50 ml of each test organism in the logarithmic growth phase (adjusted to a density of approximately 1 ϫ 10 6 to 5 ϫ 10 6 CFU/ml) to yield a drug concentration equivalent to four times the MIC. The flasks were incubated at 35°C in a shaking water bath. Aliquots were removed at 0, 2, 4, and 6 h and diluted, and 0.1 ml was plated in duplicate onto Trypticase soy agar plates. Total bacterial counts (CFU per milliliter) were determined after 18 h of incubation at 35°C. Bactericidal activity was defined as a 99.9% (Ն3 log 10 ) reduction in the total count of the original inoculum.
PAE. The postantibiotic effects (PAEs) of CL 191,121 and imipenem against clinical isolates of Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae were determined. Flasks containing 50 ml of the appropriate antimicrobial agent were inoculated with 50 ml of each test organism in the logarithmic growth phase (adjusted to a density of approximately 10 7 CFU/ml) to yield a drug concentration equivalent to four to eight times the MIC. The flasks were incubated with shaking for 2 h, followed by dilution of the culture to 1:1,000 in fresh, warm Mueller-Hinton broth. The flasks were returned to the shaker, aliquots were removed at selected time points and diluted, and 0.1 ml was plated in duplicate onto Trypticase soy agar plates. The PAE was defined as T Ϫ C, where T is the time required for the count in CFU in the test culture to increase 1 log 10 above the count immediately after drug removal, and C is the corresponding time for the control culture (2) . None of the carbapenems demonstrated activity against the Stenotrophomonas maltophilia isolates tested. For ceftazidime-resistant K. pneumoniae isolates susceptibilities to all the carbapenems were comparable to those for the ceftazidimesusceptible isolates (twofold or lower increase in the MIC). Biapenem, imipenem, and meropenem were much more active (MIC 50 s, 0.25, 1.0, and 0.5 g/ml, respectively) than the THF carbapenems (MIC 50 s, 4 to 8 g/ml) against Pseudomonas aeruginosa isolates. The carbapenem MICs were elevated (MICs, Ն8 g/ml) for 10% of the Pseudomonas strains. CL 191,121, biapenem, and imipenem demonstrated equivalent activities (MIC 90 s, 0.5 g/ml) and were twofold more active than CL 188,624, CL 190,294, and meropenem against 24 clinical isolates of Bacteroides fragilis. Imipenem was twofold more active than CL 191,121, fourfold more active than biapenem, and four-to eightfold more active than meropenem against methicillin-susceptible staphylococci (S. aureus as well as coagulase-negative staphylococci) ( Table 2 ). None of the carbapenems exhibited activity against methicillin-resistant staphylococci (MIC 90 s, Ͼ16 g/ml). The susceptibilities of the S. pneumoniae strains varied with their susceptibilities to penicillin. The penicillin-resistant strains were less sensitive to the carbapenems than the penicillin-susceptible strains. The THF carbapenems, biapenem, and imipenem all had similar activities against penicillin-susceptible (MIC 90 s, Յ0.015 g/ml) and penicillin-intermediate (MIC 90 s, 0.12 g/ml) strains. CL 191,121, imipenem, and biapenem were twofold more active (MIC 90 s, 1 g/ml) than meropenem against penicillin-resistant strains of S. pneumoniae. All the carbapenems had excellent activities (MIC 90 s, Յ0.06 g/ml) against Streptococcus pyogenes. CL 191,121 and imipenem were twofold more active than biapenem and fourfold more active than meropenem against S. agalactiae. CL 191,121 and imipenem had moderate activities (MIC 90 s, 1 g/ml) against E. faecalis isolates. Biapenem and meropenem were two-and fourfold less active, respectively, than CL 191,121 and imipenem. All the carbapenems displayed poor activities (MIC 90 s, 64 to Ͼ128 g/ml) against the E. faecium isolates tested.
RESULTS

The in vitro activities
Each of the carbapenems demonstrated fairly rapid cidal activities against E. coli 311 and S. aureus Smith by time-kill curve studies (Fig. 2 and 3, respectively) . At 6 h the THF carbapenems demonstrated bactericidal activity (Ͼ1 log 10 ) greater than those of biapenem, imipenem, and meropenem against E. coli 311. The use of CL 191,121 and CL 188,624 resulted in slightly greater reductions in viable cell counts (Ͻ1 log 10 ) than the use of CL 190,294, biapenem, meropenem, and imipenem against the S. aureus strain.
Both CL 191,121 and imipenem exerted similar PAEs (0.7 and 0.9 h, respectively) against S. aureus PT4308, while the PAE of CL 191,121 was approximately 40% longer than that of imipenem (1.3 and 0.9 h, respectively) against the other S. aureus clinical isolate tested ( Table 3 ). The PAEs of CL 191,121 and imipenem against the gram-negative isolates E. coli 311 and K. pneumoniae PT4696 were comparable, with the duration of the effect being between 1.3 and 1.6 h.
DISCUSSION
The carbapenems represent highly potent antimicrobial agents. Imipenem, biapenem, and meropenem have been extensively investigated and demonstrate excellent in vitro activities (7, 15, 20 
